Limited Research
5-Amino-1MQ
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.
View research
Emerging Research
Adipotide (Prohibitin‑TP01)
Adipotide (Prohibitin‑TP01) is a chimeric, adipose‑vasculature–targeted peptidomimetic that homes to prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro‑apoptotic…
View research
Extensively Studied
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (hGH amino acids 177-191) with an N-terminal tyrosine, developed by Professor Frank Ng at Monash University in collaboration with Metabolic…
View research
Well Researched
Cagrilintide
Cagrilintide (AM833) is a novel long-acting lipidated amylin analog that acts as a dual amylin and calcitonin receptor agonist.
View research
Emerging Research
Eloralintide
Eloralintide (LY3841136) is a novel once-weekly, selective AMY1R amylin receptor agonist developed by Eli Lilly for the treatment of obesity.
View researchL-Carnitine
L-Carnitine (levocarnitine) is a naturally occurring amino acid derivative essential for transporting long-chain fatty acids into mitochondria for energy production via beta-oxidation.
View research
Limited Research
Lipo-C
Lipo-C is a lipotropic injection containing Methionine, Inositol, Choline (MIC), and B vitamins that support fat metabolism and liver function.
View research
Extensively Studied
Mazdutide
Mazdutide (IBI362/LY3305677) is a first-in-class dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, and a synthetic analog of oxyntomodulin.
View researchOrforglipron (Foundayo)
Orforglipron (brand name Foundayo) is an FDA-approved oral, non-peptide GLP-1 receptor agonist and the first small-molecule GLP-1 approved for weight management.
View research
Extensively Studied
Retatrutide
Retatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors.
View researchSemaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic injectable or Rybelsus oral) and chronic weight management (as…
View research
Extensively Studied
Survodutide
Survodutide (BI 456906) is an investigational dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist designed for once-weekly subcutaneous administration.
View research